Drug Profile
Lerdelimumab
Alternative Names: 6B1; Anti-TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; Anti-transforming-growth-factor-beta-2 monoclonal antibody - Cambridge Antibody Technology; CAT 152; Human anti-TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; TGF-beta-2 monoclonal antibody - Cambridge Antibody Technology; TrabioLatest Information Update: 22 Dec 2016
Price :
$50
*
At a glance
- Originator Cambridge Antibody Technology
- Class Eye disorder therapies; Monoclonal antibodies
- Mechanism of Action Transforming growth factor beta2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cataracts; Proliferative vitreoretinopathy; Scars
Most Recent Events
- 27 Jun 2005 Discontinued - Phase-II for Proliferative vitreoretinopathy in United Kingdom (unspecified route)
- 27 Jun 2005 Discontinued - Preclinical for Cataracts (unspecified route)
- 23 Mar 2005 Discontinued - Phase-II/III for Scars prevention in USA (unspecified route)